

Major Depressive Disorder - Pipeline Insight, 2021

<https://marketpublishers.com/r/M7A4E532B6A4EN.html>

Date: May 2021

Pages: 120

Price: US\$ 2,500.00 (Single User License)

ID: M7A4E532B6A4EN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Major Depressive Disorder – Pipeline Insight, 2021," report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Major Depressive Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Major Depressive Disorder Understanding

Major Depressive Disorder: Overview

Major Depressive Disorder (MDD), also referred as depression, is a serious medical illness that disrupts a person's mood, behavior, thought processes, apart from degrading the physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. Sadness and grief are normal reactions to life stresses. With time, and usually without medical treatment, sadness and grief lift, and people go on with their lives. By contrast, without specialized medical treatment, depression often persists. But with effective treatment, a large majority of people improve significantly. In most instances, MDD is a recurrent, episodic illness. Depression does not have a single cause. It can be triggered, or it may occur

spontaneously without being associated with a life crisis, physical illness or other risk. Clinical suspicion is key to the diagnosis of MDD. Patients should be asked about depressed mood and/or lack of interest or pleasure when they present with nonspecific symptoms suggestive of depression. Clinicians should evaluate the patient for the following features: onset, duration, accompanying psychological symptoms, possible psychosocial precipitating factors (e.g., relationship problems, work-related stressors, or living conditions), and the effect of these symptoms on the patient's daily life and function. Brain chemistry may contribute to an individual's depression and may factor into their treatment. Antidepressants may produce some improvement within the first week or two of use yet full benefits may not be seen for two to three months.

'Major Depressive Disorder - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Major Depressive Disorder pipeline landscape is provided which includes the disease overview and Major Depressive Disorder treatment guidelines. The assessment part of the report embraces, in depth Major Depressive Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Major Depressive Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Major Depressive Disorder.

Major Depressive Disorder Emerging Drugs Chapters

This segment of the Major Depressive Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Major Depressive Disorder Emerging Drugs

AXS-05: Axsome Therapeutics

AXS-05 is a novel, oral, investigational drug product under development for the treatment of central nervous system (CNS) disorders. It utilizes Axsome's technology of combining bupropion and dextromethorphan. Dextromethorphan is an NMDA receptor antagonist, sigma-1 receptor agonist, and inhibitor of the serotonin and norepinephrine transporters. Bupropion serves to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor, and a nicotinic acetylcholine receptor antagonist. The U.S. Food and Drug Administration (FDA) has granted Priority Review to Axsome Therapeutics' AXS-05 (dextromethorphan-bupropion).

Cariprazine: Allergan

Cariprazine (VRAYLAR) is an oral, once daily atypical antipsychotic approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder, with a recommended dose range of 3 to 6 mg/day, and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5 to 6 mg/day. The drug is being evaluated in Phase III clinical trials for the treatment of patients with major depressive disorder.

SAGE-217: SAGE therapeutics

SAGE-217 is a novel, highly potent and selective, next-generation, an oral, positive allosteric modulator that has been optimized for selectivity to synaptic and extrasynaptic GABAA receptors. The Binding sites for NASs are distinct from the recognition sites for GABA, benzodiazepines, and barbiturates. The GABA system is the major inhibitory signaling pathway of the brain and central nervous system (CNS), and contributes significantly to regulating CNS function. SAGE-217 is currently being developed for major depressive disorder (MDD) and certain other mood and movement disorders.

Seltorexant: Janssen Research & Development

Seltorexant (former developmental code names MIN-202, JNJ-42847922, JNJ-922) is a

selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD). The clinical trials are being carried out for the treatment of major depressive disorder in phase III stage of development.

Brexpiprazole: Otsuka Pharmaceutical

Brexpiprazole was discovered by Otsuka and is being co-developed by Otsuka and Lundbeck in Phase III stage of development. The mechanism of action for brexpiprazole in the adjunctive treatment of major depressive disorder or schizophrenia is not fully understood. However, the efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT_{1A} and dopamine D₂ receptors, and antagonist activity at serotonin 5-HT_{2A} receptors. Brexpiprazole exhibits high affinity (sub-nanomolar) for these receptors as well as for noradrenaline alpha_{1B/2C} receptors.

PRAX 114: Praxis Precision Medicines

PRAX 114 is an orally administered GABA_A positive allosteric modulator (PAM), being developed by Praxis Precision Medicines, for the treatment of epilepsy, depression (depressive disorders in developmental table) and major depressive disorder.

SEP 4199: Sunovion Pharmaceuticals

SEP 4199 is a therapeutic candidate being developed by Sunovion Pharmaceuticals. It is a non-racemic ratio of amisulpride enantiomers. The investigational oral medicine is said to have increased potency for serotonin 5-HT₇ receptors relative to dopamine D₂ receptors. SEP-4199 was designed to increase levels of serotonin 5-HT₇ activity intended to enhance antidepressant efficacy and produce reduced levels of D₂ receptor occupancy appropriate for the treatment of bipolar depression.

Further product details are provided in the report

Major Depressive Disorder: Therapeutic Assessment

This segment of the report provides insights about the different Major Depressive Disorder drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Major Depressive Disorder

There are approx. 50+ key companies which are developing the therapies for Major Depressive Disorder. The companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Preregistration include, Axsome Therapeutics.

Phases

DelveInsight's report covers around 50+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Major Depressive Disorder: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Major Depressive Disorder therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Major Depressive Disorder drugs.

Major Depressive Disorder Report Insights

Major Depressive Disorder Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Major Depressive Disorder Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Major Depressive Disorder drugs?

How many Major Depressive Disorder drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Major Depressive Disorder?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Major Depressive Disorder therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Major Depressive Disorder and their status?

What are the key designations that have been granted to the emerging drugs?

Contents

Introduction

Executive Summary

Major Depressive Disorder: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Major Depressive Disorder – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Major Depressive Disorder companies' collaborations, Licensing, Acquisition -Deal

Value Trends

Major Depressive Disorder Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Preregistration)

Comparative Analysis

AXS-05: Axsome Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

SEP 4199: Sunovion Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early stage products (Phase I/II)

Comparative Analysis

SPL026: Small Pharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Major Depressive Disorder Key Companies

Major Depressive Disorder Key Products

Major Depressive Disorder- Unmet Needs

Major Depressive Disorder- Market Drivers and Barriers

Major Depressive Disorder- Future Perspectives and Conclusion

Major Depressive Disorder Analyst Views

Major Depressive Disorder Key Companies

Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Major Depressive Disorder
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Major Depressive Disorder
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Major Depressive Disorder - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/M7A4E532B6A4EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M7A4E532B6A4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970